Department of Gastroenterology and Hepatology, University Hospital Zürich, Sternwartstr. 14, 8097, Zurich, Switzerland.
Department of Clinical Research, Department of Hepatology, University of Bern, Bern, Switzerland.
J Mol Med (Berl). 2017 Oct;95(10):1077-1089. doi: 10.1007/s00109-017-1556-y. Epub 2017 Jul 8.
Alcoholic liver disease (ALD) is a leading cause of liver cirrhosis, liver cancer, and related mortality. The endocannabinoid system contributes to the development of chronic liver diseases, where cannabinoid receptor 2 (CB2) has been shown to have a protecting role. Thus, here, we investigated how CB2 agonism by 4'-O-methylhonokiol (MHK), a biphenyl from Magnolia grandiflora, affects chronic alcohol-induced liver fibrosis and damage in mice. A combination of alcohol (10% vol/vol) and CCl4 (1 ml/kg) was applied to C57BL/6 mice for 5 weeks. MHK (5 mg/kg) was administered daily, and liver damage assessed by serum AST and ALT levels, histology, gene, and protein expression. Endocannabinoids (ECs) and related lipid derivatives were measured by liquid chromatography and mass spectrometry (LC-MS) in liver tissues. In vitro, MHK was studied in TGFβ1-activated hepatic stellate cells (HSC). MHK treatment alleviated hepatic fibrosis, paralleled by induced expression of matrix metalloproteinases (MMP)-2, -3, -9, and -13, and downregulation of CB1 mRNA. Necrotic lesions and hepatic inflammation were moderately improved, while IL-10 mRNA increased and IFNγ, Mcl-1, JNK1, and RIPK1 normalized by MHK. Hepatic anandamide (AEA) and related N-acetylethanolamines (NAEs) were elevated in MHK group, whereas fatty acid synthase and diacylglycerol O-acyltransferase 2 expression reduced. In vitro, MHK prevented HSC activation and induced apoptosis via induction of bak1 and bcl-2. To conclude, MHK revealed hepatoprotective effects during alcohol-induced liver damage through the induction of MMPs, AEA, and NAEs and prevention of HSC activation, indicating MHK as a potent therapeutic for liver fibrosis and ALD.
Methylhonokiol improves liver damage and survival. Methylhonokiol reduces hepatic fibrosis and necroinflammation. Methylhonokiol prevents myofibroblast activation and induces apoptosis. Methylhonokiol upregulates endocannabinoids and related N-acylethanolamines. Methylhonokiol contributes to lipid hydrolysis via PPARα/γ.
酒精性肝病 (ALD) 是肝硬化、肝癌和相关死亡的主要原因。内源性大麻素系统有助于慢性肝病的发展,其中大麻素受体 2 (CB2) 已被证明具有保护作用。因此,在这里,我们研究了来自 Magnolia grandiflora 的双苯 4'-O-甲基厚朴酚 (MHK) 通过 CB2 激动作用如何影响慢性酒精诱导的肝纤维化和损伤。将酒精 (10%vol/vol) 和 CCl4 (1ml/kg) 的混合物应用于 C57BL/6 小鼠 5 周。每天给予 MHK(5mg/kg),并通过血清天冬氨酸转氨酶和丙氨酸转氨酶水平、组织学、基因和蛋白质表达评估肝损伤。通过液相色谱和质谱 (LC-MS) 测量肝组织中的内源性大麻素 (ECs) 和相关脂质衍生物。在体外,研究了 TGFβ1 激活的肝星状细胞 (HSC) 中的 MHK。MHK 治疗减轻了肝纤维化,同时诱导基质金属蛋白酶 (MMP)-2、-3、-9 和 -13 的表达,并下调 CB1mRNA。坏死病变和肝炎症得到适度改善,而 MHK 增加了 IL-10mRNA,使 IFNγ、Mcl-1、JNK1 和 RIPK1 正常化。肝大麻素 (AEA) 和相关 N-乙酰乙醇胺 (NAE) 在 MHK 组中升高,而脂肪酸合酶和二酰甘油 O-酰基转移酶 2 的表达降低。在体外,MHK 通过诱导 bak1 和 bcl-2 来防止 HSC 激活和诱导细胞凋亡。总之,MHK 通过诱导 MMPs、AEA 和 NAE 以及防止 HSC 激活,在酒精诱导的肝损伤中显示出肝保护作用,表明 MHK 是治疗肝纤维化和 ALD 的有效药物。
甲基厚朴酚改善酒精性肝损伤引起的肝损伤和存活率。甲基厚朴酚减少肝纤维化和坏死性炎症。甲基厚朴酚防止肌成纤维细胞激活并诱导细胞凋亡。甲基厚朴酚上调内源性大麻素和相关 N-乙酰乙醇胺。甲基厚朴酚通过 PPARα/γ 促进脂质水解。